ATAC - Endometrial Sub-Protocol

NCT00814125 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 285

Last updated 2009-05-01

No results posted yet for this study

Summary

To compare the difference between the ARIMIDEX group and the tamoxifen group in the incidence of abnormal endometrial histological findings arising after treatment has commenced.

Conditions

Interventions

DRUG

Anastrozole (Arimidex)

1mg, orally, once daily

DRUG

Tamoxifen (Nolvadex)

20mg, orally, once daily

DRUG

Nolvadex placebo

DRUG

Arimidex placebo

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-06-30
Completion
2005-12-31

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00814125 on ClinicalTrials.gov